Overview

Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)

Status:
Completed

Trial end date:
2009-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the efficacy, safety and tolerability of rabeprazole extended release (ER) 50 mg with placebo in subjects with symptomatic gastroesophageal reflux disease (sGERD).

Phase:

Phase 3

Details

Lead Sponsor:

Eisai Inc.

Treatments:

Rabeprazole